I would like to welcome you to the web pages of the Division of Hematology Oncology and hope that you will find the information on our site helpful and informative.
It is a privilege to lead these extraordinarily talented faculty members during this period of transition. Over the last 5 years division has seen tremendous growth, the size of our faculty has been increasing at an unprecedented pace. We have added more than 29 new faculty members, and more are on the way.
Some of our faculty members have a primary focus on providing state-of-the-art clinical care to patients while others have a primary focus on clinical, translational or basic research in blood diseases and cancer. All faculty members contribute to advancing the field in different ways, either through leading clinical trials, enrolling patients in clinical trials, conducting fundamental laboratory research or educating the next generation of leaders in the field. Our faculty work closely and collaboratively with other faculty in our Academic Health Center in multidisciplinary clinics, tumor boards, and academically focused, disease-based groups.
At the same time, we are making strides in enhancing the education of our trainees through our Fellowship Programs. We have markedly enhanced the educational offerings for the benefit of our fellows. We now provide our fellows with more research opportunities than ever before. In addition to the traditional fellowship training in Hematology Oncology, we have two highly specialized fellowships available in Experimental Therapeutics and in Hematological Malignancies and Bone Marrow Transplantation.
The laboratory research programs of the Division of Hematology Oncology are also in a phase of rapid expansion. Examples of the areas of research focus in the Division include, research on the cell cycle and DNA repair, mTOR signaling in cancer, proteasome biology in multiple myeloma, immunotherapy of lung and head and neck cancer, nanoparticle therapeutics, prostate cancer, sickle cell disease, tissue factor in blood coagulation and cancer metabolics of cancer cells, and the biology of primary and metastatic brain tumors.
We expect the growth of the clinical, educational and research programs of the Division to continue in the next 5 years. Our disease specific inter-disciplinary programs in solid tumor oncology and hematologic malignancies including bone marrow transplantation are continuing the tripartite mission of the Division to enhance research, education and quality clinical care. In the coming year we will be strengthening and expanding our Palliative Care Program realizing the need and importance of symptom management for our patients. We also expect to continue to develop a number of similar specialized clinical programs in blood disorders the near future.
We invite you to revisit this site on a regular basis to learn more about what we are doing to become one of the elite hematology oncology divisions in the country.
Tahir Latif MD MBA, FACP
Interim Division Director